enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Adecatumumab - Wikipedia

   en.wikipedia.org/wiki/Adecatumumab

   It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. [1] Adecatumumab has been used in clinical studies of treatment in colorectal, prostate [2] and breast cancers. [3] Phase II results were published ...

3. Abituzumab - Wikipedia

   en.wikipedia.org/wiki/Abituzumab

   Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]

4. Tocilizumab - Wikipedia

   en.wikipedia.org/wiki/Tocilizumab

   It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.

5. Ipilimumab - Wikipedia

   en.wikipedia.org/wiki/Ipilimumab

   They then injected intact antibodies and demonstrated that CTLA-4 blockade enhanced T cell responses in mice responding to vaccines and to super antigens. [77] Leach, a new postdoctoral fellow, was tasked by Allison with applying these in tumor models. Antibody-treated mice showed significantly less cancer growth than the controls. [16]

6. Monoclonal antibody therapy - Wikipedia

   en.wikipedia.org/wiki/Monoclonal_antibody_therapy

   Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.

7. Carlumab - Wikipedia

   en.wikipedia.org/wiki/Carlumab

   Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis, [8] [9] castration-resistant metastatic prostate cancer [1] [10] and solid tumors. [ 11 ] [ 12 ] Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 [ 13 ] due to limited success in clinical trials.